Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Oct 24, 2024Diagnostic algorithm shown to detect early signs of worsening heart failure and reduce hospitalisations for patients with cardiac implantable electronic devices
HEMEL HEMPSTEAD, United Kingdom, 24 October, 2024 – Boston Scientific (NYSE: BSX) announced that the National Institute for Health and Care Excellence (NICE), which provides evidence-based...
-
Sep 9, 2024Un sondaggio dimostra che depressione e stanchezza sono comuni tra le persone che vivono con il dolore cronico
MILANO, Italia, 9 Settembre 2024 – Il mese di settembre è dedicato alla sensibilizzazione sul dolore cronico, una condizione che colpisce più di 10 milioni di persone in Italia1. Boston...
-
Sep 9, 2024Befragung zeigt, dass junge Menschen in Folge chronischer Schmerzen mit Depressionen und Angstzuständen zu kämpfen haben.
Düsseldorf, Deutschland – 09. September 2024 – Eine neue Umfrage unter Menschen mit chronischen Schmerzen in Deutschland zeigt die teils deutlichen Auswirkungen chronischer Schmerzen auf die...
-
Sep 9, 2024Responses of 1,000 people with chronic pain in the UK reveal the far-reaching burden of chronic pain on mental health, with many feeling misunderstood
HEMEL HEMPSTEAD, United Kingdom – 9 September, 2024 – A new survey highlights the profound impact chronic pain has on the lives of people living in the UK, often severely affecting their...
-
Aug 27, 2024
Boston Scientific Corporation (NYSE: BSX) today announced it has obtained CE mark for the ACURATE Prime™ Aortic Valve System, the newest transcatheter aortic valve replacement (TAVR) technology...
-
Jun 20, 2024Vercise™ Neural Navigator 5 con tecnologia STIMVIEW™ XT è progettato per semplificare la procedura per le persone affette da patologie neurologiche.
HEMEL HEMPSTEAD, Regno Unito – Giovedì 20 giugno 2024 – Boston Scientific Corporation (NYSE: BSX) ha ottenuto il marchio CE per il software Vercise™ Neural Navigator 5 con tecnologia...
-
Jun 20, 2024Vercise™ Neural Navigator 5 con tecnología STIMVIEW™ XT está diseñado para agilizar el procedimiento para las personas que viven con afecciones neurológicas
Madrid, 20 de junio de 2024 – Boston Scientific Corporation (NYSE: BSX) ha obtenido la aprobación del marcado CE para su Software Vercise™ Neural Navigator 5 con tecnología STIMVIEW™ XT....
-
Jun 20, 2024Vercise™ Neural Navigator 5 mit STIMVIEW™ XT-Technologie soll das Verfahren für Menschen mit neurologischen Störungen vereinfachen
DÜSSELDORF – 20. Juni 2024 – Die Boston Scientific Corporation (NYSE: BSX) hat die CE-Kennzeichnung für die Vercise™ Neural Navigator 5 Software mit STIMVIEW™ XT Technologie erhalten,...
-
Jun 20, 2024Vercise™ Neural Navigator 5 with STIMVIEW™ XT technology is designed to streamline procedure for people living with neurological conditions
HEMEL HEMPSTEAD, United Kingdom – 20 June 2024 – Boston Scientific Corporation (NYSE: BSX) has obtained CE Mark on the Vercise™ Neural Navigator 5 Software with STIMVIEW™ XT technology,...
-
Jan 8, 2024Acquisition to expand urology portfolio with differentiated technologies to treat urinary and bowel dysfunction
Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Axonics, Inc. (Nasdaq: AXNX), a publicly traded medical technology company primarily...
-
Dec 12, 2023El nuevo acuerdo de compra de energía virtual (VPPA, por sus siglas en inglés) contribuye a alcanzar las ambiciones de descarbonización de la compañía en su camino hacia cero emisiones
MADRID, ESPAÑA, 12 de diciembre de 2023 – Boston Scientific Corporation (NYSE: BSX) ha activado su primer acuerdo europeo de compra de energía virtual (Virtual Power Purchasing Agreement en inglés) junto a BayWa r.e., empresa alemana líder en el desarrollo de energía renovable y proveedora de soluciones que impulsará a la compañía a cumplir sus objetivos de descarbonización.
-
Dec 12, 2023New virtual power purchase agreement helps to advance the company’s decarbonisation goals on its path to net zero
MADRID, SPAIN, 12 December 2023 – Boston Scientific Corporation (NYSE: BSX) has activated its first European virtual power purchase agreement (VPPA) with leading renewable energy developer and solutions provider BayWa r.e., helping the company make progress on its decarbonisation targets.
-
Sep 5, 2023Viele Menschen mit chronischen Schmerzen sind laut Umfrage bereits in jungen Jahren betroffen und Frauen fühlen sich mit ihren Schmerzen vom Umfeld wenig verstanden.
Düsseldorf – 5. September 2023 – Boston Scientific veröffentlichte heute Ergebnisse einer repräsentativen Befragung von 1.000 Menschen mit chronischen Schmerzen, laut denen dieses Leiden in...
-
Sep 5, 2023Research conducted in the United Kingdom for pain awareness month points to a gender difference in the experience of chronic pain, pursuing pain relief and the feeling of being understood
HEMEL HEMPSTEAD, United Kingdom – 5 Sept. 2023 – Boston Scientific (NYSE: BSX) today revealed survey results of 2,000 people living with chronic pain in the United Kingdom (UK) that unveiled...
-
May 18, 2023Taoiseach Leo Varadkar joins company’s 25-year anniversary celebrations in Clonmel
Taoiseach Leo Varadkar joins company’s 25-year anniversary celebrations in Clonmel CLONMEL, IRELAND (19 May 2023) - Boston Scientific Corporation (NYSE: BSX) will today announce an €80 million...
-
Nov 29, 2022
Acquisition to expand endoluminal surgery portfolio and add differentiated technologies for endobariatric procedures MARLBOROUGH, Mass., Nov. 29, 2022 /PRNewswire/ -- Boston Scientific Corporation...
-
Nov 8, 2022El algoritmo de doble etapa detecta y verifica posibles arritmias cardíacas para ayudar a aumentar la eficiencia clínica
MADRID, 8 de noviembre de 2022 - Boston Scientific ha anunciado hoy, a la comunidad médico-científica especializada, el lanzamiento en Europa del Sistema de Monitor Cardíaco Insertable (MCI)...
-
Nov 8, 2022Zweistufiger Algorithmus erkennt und überprüft potenzielle Herzrhythmusstörungen, um klinische Wirksamkeit zu steigern
Düsseldorf, 8. November 2022 – Die Boston Scientific Corporation (NYSE: BSX) gab heute die Markteinführung des LUX-Dx Insertable Cardiac Monitor (ICM) Systems in Europa bekannt. Das...
-
Nov 8, 2022Algoritmo a doppia fase per verificare potenziali aritmie cardiache
Milano, 8 novembre 2022 - Boston Scientific Corporation (NYSE: BSX) ha annunciato oggi l’introduzione in Europa del nuovo monitor cardiaco inseribile LUX-Dx™ (ICM), un dispositivo diagnostico...
-
Nov 8, 2022Dual-stage algorithm detects and verifies potential heart arrhythmias to help increase clinical efficiency
LONDON, November 8, 2022 – Boston Scientific Corporation (NYSE: BSX) today announced the European launch of the LUX-Dx™ Insertable Cardiac Monitor (ICM) System, a long-term diagnostic device...
-
Jun 21, 2022
Ripristinare funzioni vitali e qualità di vita dopo l’asportazione di un tumore alla prostata: le opzioni terapeutiche risolutive e sostenibili per l’incontinenza urinaria maschile Milano, 21...
-
Apr 14, 2022Taoiseach Micheál Martin welcomes new expansion that is expected to enable 300+ jobs in coming years
BOSTON SCIENTIFIC ANNOUNCES €100M INVESTMENT IN GALWAY CAMPUS Taoiseach Micheál Martin welcomes new expansion that is expected to enable 300+ jobs in coming years GALWAY, IRELAND (14 April...
-
Apr 4, 2022More UK patients with Benign Prostatic Enlargement (BPE) should now have improved access to these treatments thanks to inclusion in medtech funding pathway
HEMEL HEMPSTEAD, UK., Mon 4 April, 2022– Boston Scientific Corporation (NYSE: BSX) is pleased to announce the inclusion of two innovative devices in this year’s NHS MedTech Funding Mandate...
-
Feb 15, 2022
MARLBOROUGH, Mass., 15. Februar 2022– Boston Scientific Corporation (NYSE: BSX) hat heute den Abschluss seiner Übernahme von Baylis Medical Company Inc. bekannt gegeben, einem Unternehmen, das...